BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With BCMA-positive Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03093168
• Other study ID #: anti-BCMA CART
• Status: Recruiting
• Phase: Phase 1
• Start date: February 15, 2017
• Est. completion date: February 2020

Study information

• Verified date: March 2018
• Source: The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

Description:

Primary Objectives

1. To determine the feasibility ad safety of BCMA CAR-T cells in treating patients with multiple myeloma.

2. To determine in vivo dynamics and persistency of BCMA CAR-T cells.

3. To access the efficacy of BCMA CAR-T cells in patients with multiple myeloma.

Secondary Objectives

1. To assess the bone marrow and tumor migration of BCMA CAR-T cells.

2. To investigate the tumor killing capability of BCMA CAR-T cells in vitro

3. To investigate the possibility of host immune response to the mouse derived BCMA scFv, and evaluate its correlation to CAR-T persistence.

4. To correlate the subsets and differentiation of BCMA CAR-T cells to observed anti-tumor efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: February 2020
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Expected survival > 12 weeks

• Diagnosis of Multiple Myeloma by MWG criteria 20

• Patients previously received at least 3 different prior treatment regimens for multiple myeloma, including alkylating agent, protein inhibitors, and immunomodulator, and have disease progression in the past 60 days

• Important organs function enough to tolerate this therapy

• At least 90 days after stem cell transplantation

• Clinical performance status of ECOG score 0-4

• Accessible to intravenous injection, and no white blood cell collection contraindications

• Sexually active patients must be willing to utilize one of the more effective birth control methods for 30 days after the CTL infusion. Male partner should use a condom

• Able to understand and sign the Informed Consent Document.

Exclusion Criteria:

• Patients with symptoms of central nervous system

• Patients with second malignancies in addition to multiple myeloma

• Active hepatitis B or C, HIV infections

• Any other active diseases could affect the enrollment of this trial

• Suffering severe cardiovascular or respiratory disease

• Poorly controlled hypertension

• Long term use of immunosuppressive agents after organ transplantation, except currently receiving or recently received glucocorticoid treatment

• A history of mental illness and poorly controlled

• Screening showing target cell transduction efficacy is lower than 30%, or T cell proliferation is not enough for infusion (less than 5 fold)

• Occurrence of unstable pulmonary embolism, deep vein thrombosis, or other major arterial/venous thromboembolic events 30 days prior to assignment

• Women of child-bearing potential who are pregnant or breastfeeding during therapy, or have a planned pregnancy with 2 months after therapy

• Women of child-bearing potential who are not willing to practice birth control from the time of enrollment on this study and for 2 months after receiving the preparative regimen. Women of child bearing potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion

• Active systemic infections or uncontrolled infection within 14 days prior enrollment

• Subjects suffering disease affects the understanding of informed consent or complying with study protocol

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• Anti-BCMA CAR-T cells
Retroviral vector-transduced autologous T cells to express anti-BCMA CAR

Drug:
• Fludarabine
dose: 25mg/m2/d
• Cyclophosphamide
Dose: 40mg/kg

Locations

Country	Name	City	State
China	Henan Province of TCM	Zhengzhou	Henan

Sponsors (4)

Lead Sponsor	Collaborator
The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine	First Affiliated Hospital of Wenzhou Medical University, Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0	Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0	6 months
Secondary	Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm	Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm	8 weeks
Secondary	Duration of CAR-positive T cells in circulation	Duration of CAR-positive T cells in circulation	6 months
Secondary	Total number of CAR-positive T cells infiltrated into lymphoma tissue	Total number of CAR-positive T cells infiltrated into lymphoma tissue	6 months